4th Quarter 2012

Focused commercial product development

and

Roadmap to value creation

Paul de Potocki, CEO
Ruben Ekbråten, CFO
Magnus Sjögren, CMO

Disclaimer

This document (the "Presentation") has been prepared by DiaGenic ASA (the "Company") exclusively for information purposes. Neither this Presentation nor any copy of it nor the information contained herein is being issued, and nor may this Presentation nor any copy of it nor the information contained herein be distributed directly or indirectly to or into, any jurisdiction in which such distribution would be unlawful or not appropriate. Recipients of the Presentation shall not reproduce, redistribute or pass on, in whole or in part, the Presentation or any of its content to any other person. The Presentation does not constitute, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, and are sometimes identified by the words "believes", expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that are expressed or implied by statements and information in the Presentation, including, among others, risks or uncertainties associated with the Company's business, segments, development, growth management, financing, market acceptance and relations with customers, and, more generally, general economic and business conditions, changes in domestic and foreign laws and regulations, taxes, changes in competition and pricing environments, and fluctuations in currency exchange rates and interest rates. None of the Company or any of its subsidiaries or any such person's directors, employees or advisors provide any assurance that the assumptions underlying forward-looking statements expressed in this Presentation are free from errors nor does any of them accept any responsibility for the future accuracy of such forward-looking statements.

The information contained in this Presentation has not been independently verified. No representation or warranty (express or implied) is made as to the accuracy or completeness of any information contained herein, and it should not be relied upon as such. None of the Company or its subsidiaries or any such person's directors, employees or advisors shall have any liability whatsoever arising directly or indirectly from the use of this Presentation. By reading the Presentation, or attending any oral presentation held in relation thereto, you acknowledge that you will be solely responsible for your own assessment of the Company, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business. The content of this Presentation are not to be construed as legal, business, investment or tax advice. Each recipient should consult with its own professional advisors for any such matters and advice.

No action has been taken to allow the distribution of this Presentation in any jurisdictions other than Norway. The Presentation has not been reviewed or registered with, or approved by, any public authority, stock exchange or regulated market. The distribution of this Presentation, as well as any subscription, purchase, sale or transfer of securities issued by the Company, may be restricted by law in certain jurisdictions, and persons into whose possession this Presentation comes are required by the Company to inform themselves about and comply with any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction. None of the Company or its subsidiary undertakings or any such person's directors, employees or advisors shall have any responsibility for any such violations.

THIS PRESENTATION AND THE INFORMATION CONTAINED HEREIN DO NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND ARE NOT FOR PUBLICATION OR DISTRIBUTION TO U.S. PERSONS (WITHIN THE MEANING OF REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")). THE SECURITIES OF THE COMPANY HAVE NOT AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO U.S. PERSONS, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.

IN RELATION TO THE UNITED KINGDOM, THE PRESENTATION IS STRICTLY CONFIDENTIAL AND IS ONLY DIRECTED AT PERSONS WHO FALL WITHIN THE MEANING OF ARTICLE 19 (INVESTMENT PROFESSIONALS) AND 49 (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 OR WHO ARE PERSONS TO WHOM THE PRESENTATION MAY OTHERWISE LAWFULLY BE DISTRIBUTED.

There may have been changes in matters which affect the Company subsequent to the date of this Presentation. Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, except as required by law, to update or correct any information included in this Presentation.

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of the Norwegian courts.

Agenda

- Highlights
- Market needs
- Product development
- Financial results
- Financing and Outlook

Highlights

- Product development of new ADtect® and MCItect® are progressing as planned.
  Both products are undergoing technical verification studies and calibration trials. Final confirmatory validation studies will be performed during the spring, allowing CE markings around mid-2013

- The collaborative clinical study with GE Healthcare and Lund's University for AMYtect™ is progressing as planned. An interim analysis is planned for the summer and results are expected in Q3 this year

- DiaGenic is preparing a pre-IDE meeting with the FDA during the summer, with the aim to confirm the clinical and regulatory path to U.S. approval and commercial launch of MCItect®

Highlights cont.

- DiaGenic, together with its financial advisors, are in dialogue with existing shareholders and potential new institutional and industrial investors with the aim to complete an equity issue.
  The indicative size of the issue is NOK 30 million, which will provide funding for Company operations at least until end of first quarter 2014. The Company's largest shareholders have given positive indications regarding their participation in an issue at the current market price level

- Q4 2012 pre-tax earnings were NOK -10.9 million compared with NOK -8.7 million in Q4 2011. The cash balance was NOK 18 million at the end of the quarter, which is according to plan. Current cash balance is sufficient to fund the company until early May 2013

Agenda

- Highlights
- Market needs
- Product development
- Financial results
- Financing and Outlook

A distinct shift in how Alzheimer's disease is viewed



- Updated diagnostic guidelines by National Institute of Aging and the Alzheimer Association in 2011
- FDA Industry Guidelines for AD drug development in February 2013 emphasizing value of identifying and studying patients with early stage AD, i.e. MCI due to AD
- Pharma redirecting drug development efforts from AD dementia to MCI due to AD
- Clinical diagnosis is more challenging in earlier disease stage as MCI is a heterogeneous syndrome, increasing the need for objective biomarker tests

The need to objectively identify the patient



- Dementia can be caused by Alzheimer's disease, but also by other underlying conditions
- MCI is a clinical diagnosis that can be caused by early stage AD, but also by other conditions
- Brain amyloid is a recognized hallmark of Alzheimer's disease. Brain PET imaging allows visualization of amyloid and potentially disease progression, but which patients are eligible?

Pharma industry objectives and needs

- The Alzheimer's disease drug market was worth $5.8bn in 2011, forecasted to grow to $14.5bn - 20bn by 2020
- Correct patient inclusion in clinical trials to demonstrate drug effect
- New and expensive drug therapies expected to increase need and value of objective patient diagnosis prior to initiation of treatment



Alzheimer's disease market needs…

- Prevent anticipated explosion of society costs related to AD dementia
- Enable new drug therapies that reverse, prevent or delay onset of AD dementia
- Objective patient identification across disease progression, allowing appropriate intervention and therapy at applicable stage of disease

…and DiaGenic's contributions

DiaGenic's portfolio of diagnostic products aims to:

- Aid in objective, patient friendly and cost effective diagnosis across Alzheimer's disease progression
- Respond to the Pharma industry's need to identify patients eligible for drug treatment
- Identify patients with brain amyloid and select the appropriate patients for amyloid PET imaging

Agenda

- Highlights
- Market needs
- Product development
- Financial results
- Financing and Outlook

Product pipeline for Alzheimer's Disease

ADtect®

- To aid in the diagnosis of mild to moderate AD and to differentiate dementia due to AD from other forms of dementia
- Current data indicates differential diagnosis accuracy of 82-89%

MCItect®

- To detect patients with amnestic MCI who will progress to AD within two years
- Current data indicates test accuracy of 81%

AMYtect™

- To detect patients with brain amyloid and correlating with amyloid PET imaging. Studied in GE Healthcare collaboration

ADtect® development progress and plans

- Ability to differentiate between AD and other forms of dementia implies significantly improved clinical utility
- Current data indicates improved test accuracy of 82-89%
- Technical verification and calibration studies near completion. Final validation study performed during the spring
- CE marking planned for mid-2013
- EU distributors, US LDT and Chinese partners enable pilot market introduction

MCItect® development progress and plans



- Ability to identify AD patients who will develop dementia prior to onset of dementia constitutes a significant breakthrough
- Current data indicates improved test accuracy of 81%
- Technical verification and calibration studies near completion. Final validation study performed during the spring
- CE marking planned for mid-2013
- Pre-IDE meeting with the FDA planned. U.S. clinical and regulatory plan pending strategic decision

Third party collaborations providing unique access to patient data supporting product validations

- Collaborate since 2011 with UC Davis, US
- Collaborative agreement with Harvard Medical school
- Agreement signed with AP-HP and Baltazar in France, a major multi-centre prospective study on MCI
- Agreement recently signed with major American university
- Submitted application for access to ADNI[1] samples

[1] *Alzheimer's Disease Neuroimaging Initiative*

DiaGenic publication

- "Development of blood-based gene expression tests for identification of prodromal AD and rate of progression of AD"
- Recently accepted for publication in the Journal of Alzheimer's Disease

AMYtect™ development progress and plans

- An IVD blood test to identify patients with brain amyloid that correlates with amyloid PET imaging
- Developed under a collaborative research and option agreement with GE Healthcare
- Planned 150 patients, 50 patients enrolled as of December 2012
- Interim analysis during summer, read-out expected in Q3 2013
- Ambition to complete product development in industrial partnership

AMYtect™ is directly related to marketed technology and new drugs in development

Company	Tracer	Stage
Avid Radiopharmaceuticals / Eli Lilly	Amyvid	FDA approval April 6, 2012
GE Healthcare	Flutemetamol	Positive Phase III
Piramal Healthcare	Florbetaben	Phase III
Navidea BioPharmaceuticals	18F-AZD4694	Phase II

- PET market for Alzheimer's is estimated to reach $1bn by 2020
- AMYtect™ has potential use as patient inclusion test for PET scans
- Majority of drugs in clinical development target Aβ pathway
- AMYtect™ has potential utility for the identification of early stage AD patients eligible for treatment

Sources: Nature biotechnology 30, 575 (2012). "PET tracers for Alzheimer's"
BIO TECH SYSTEMS, INC. "Market for PET radiopharmaceuticals and PET imaging, Report 320 "

Agenda

- Highlights
- Market needs
- Product development
- Financial results
- Financing and Outlook

Finance, Profit & Loss

P&L 4Q
(thousand NOK)

	4Q '12	4Q '11
Revenue	41	60
Grants	503	1,570
Operating Cost net of Grants	11,099	9,375
Operating loss	(11,057)	(9,375)
Net finance	200	595
Net income	(10,857)	(8,720)

Operating Cost
(thousand NOK)



	Q4 11	Q1 12	Q2 12	Q3 12	Q4 12
Cost of sales	245	320	110	14	223
Salaries and related	6 872	5 959	7 410	6 417	5 430
Depreciation and Write downs	222	224	225	221	797
Other operating cost	2 036	2 922	4 980	2 173	4 649

Finance, Cash position



- Cash balance end of December 2012: NOK 18 million
- Assuming no revenues, the estimated time to no cash is May 2013
- Financing process on-going
  - DiaGenic aims to complete a capital raise to provide funding for its operations at least until end of first quarter 2014. The indicative size of the equity issue is NOK 30 million

Agenda

- Highlights
- Market needs
- Product development
- Financial results
- Financing and Outlook

Roadmap for asset value creation



Financing process

- DiaGenic, together with its financial advisors, are in dialogue with existing shareholders and potential new institutional and industrial investors with the aim to complete an equity issue. The indicative size of the issue is NOK 30 million, which will provide funding for its operations at least until end of first quarter 2014

- Allows the Company to realize critical value enhancing milestones related to its product portfolio, as well as time to capitalize on a significantly more favorable position to pursue the most attractive strategic option going forward

- The Company's largest shareholders have given positive indications regarding their participation in an issue at the current market price level

Use of Proceeds

- Achieve CE marking of new ADtect® and MCItect®
- Conclude ongoing clinical study for AMYtect™
- Conduct pre-IDE meeting with the FDA
- Establish additional R&D collaborations with Pharma
- Evaluate Lab Developed Test partners in the U.S. and in China
- In parallel, evaluate strategic options going forward

Strategic options going forward



- DiaGenic intends to pursue these three alternatives in parallel going forward

Our goals for next 12 months include:

- Secure appropriate financing of the Company
- Deliver on near-term milestones related to product development:
  - CE marking of new ADtect® and MCItect® in Europe
  - Conclude on-going clinical study with GE Healthcare to identify a blood-based IVD test correlating with brain PET imaging
  - Conduct pre-IDE meeting with the FDA to verify requirements for U.S. regulatory clearance process
- Enter into additional collaborative agreements related to Alzheimer's disease with major pharmaceutical companies
- Proactively and in parallel evaluate the alternatives for strategic development following achievement of above product development milestones, providing optimal shareholder value

DiaGenic

DiaGenic ASA
Grenseveien 92, N-0663 Oslo, Norway
Tel +47 23 24 89 50
Mail: diagenic@diagenic.com
www.diagenic.com